Why have Vedolizumab therapy in China specifically?

China offers Vedolizumab therapy at a significantly lower cost—approximately $3,800 per cycle—compared to Western countries, where prices can exceed $6,000–$10,000. Chinese hospitals, particularly in major cities like Beijing and Shanghai, have JCI-accredited gastroenterology departments with experienced specialists who manage high patient volumes, ensuring proficiency in infusion protocols. Additionally, China’s streamlined medical tourism services provide coordinated care, including pre-treatment evaluation and follow-up, often with shorter wait times for appointments.